SeaStar Medical Q3 2026 Earnings Date & Estimates

SeaStar Medical (NASDAQ:ICU) (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function.

Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy. The device is designed to interact with activated immune cells in circulating blood and reduce inflammatory activity. SeaStar Medical has focused its initial development efforts on the pediatric population, particularly children with acute kidney injury and sepsis or other septic conditions who require continuous kidney replacement therapy.

The U.S. Food and Drug Administration granted a Humanitarian Device Exemption for the company’s pediatric SCD application in 2023. SeaStar Medical continues to pursue clinical development and regulatory activities for its technology, with the United States serving as its primary reported market. The company is headquartered in Denver, Colorado.